OBJECTIVES: Poor survival of high-grade serous pelvic cancer is caused by a lack of effective screening measures. The detection of exfoliated cells from high-grade serous pelvic cancer, or precursor lesions, is a promising concept for earlier diagnosis. However, collecting those cells in the most efficient way while fulfilling all requirements for a screening approach is a challenge. We introduce a new catheter for uterine and tubal lavage (UtL) and the clinical evaluation of its performance. METHODS/MATERIALS: In study I, the clinical feasibility of the UtL using the new catheter was examined in 93 patients admitted for gynecologic surgery under general anesthesia. In study II, the safety of the UtL procedure was assessed. The pain during and after the UtL performed under local anesthesia was rated on a visual analog scale by 22 healthy women. RESULTS: In study I, the UtL was carried out successfully in 92 (98.9%) of 93 cases by 16 different gynecologists. It was rated as easy to perform in 84.8% of patients but as rather difficult in cancer patients (odds ratio, 5.559; 95% confidence interval, 1.434-21.546; P = 0.007). For benign conditions, dilatation before UtL was associated with menopause status (odds ratio, 4.929; 95% confidence interval, 1.439-16.884; P = 0.016). In study II, the pain during UtL was rated with a median visual analog scale score of 1.6. During a period of 4 weeks after UtL, none of the participants had to use medication or developed symptoms requiring medical attention. The UtL took 6.5 minutes on average. The amount of extracted DNA was above the lower limit for a sensitive, deep-sequencing mutation analysis in all cases. CONCLUSIONS: Our studies demonstrate that the UtL, using the new catheter, is a safe, reliable, and well-tolerated procedure, which does not require elaborate training. Therefore, UtL fulfils all prerequisites to be used in a potential screening setting.

Department of Gynaecology and Gynaecologic Oncology Kliniken Essen Mitte Essen Germany

Department of Gynecologic Oncology Leuven Cancer Institute University Hospitals Leuven KU Leuven Leuven Belgium

Department of Gynecology and Obstetrics Faculty of Medicine and University Hospital in Pilsen Charles University Prague Pilsen Czech Republic

Molecular Oncology Group Department of Obstetrics and Gynecology Comprehensive Cancer Center Gynecologic Cancer Unit Medical University of Vienna Vienna Austria

Zobrazit více v PubMed

Baldwin LA, Huang B, Miller RW, et al. Ten-year relative survival for epithelial ovarian cancer. Obstet Gynecol. 2012;120:612–618. PubMed

Rosenthal AN, Fraser LSM, Philpott S, et al. Evidence of stage shift in women diagnosed with ovarian cancer during phase II of the United Kingdom Familial Ovarian Cancer Screening Study. J Clin Oncol. 2017;35:1411–1420. PubMed PMC

Jacobs IJ, Menon U, Ryan A, et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet. 2016;387:945–956. PubMed PMC

Finch AP, Lubinski J, Møller P, et al. Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol. 2014;32:1547–1553. PubMed PMC

Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010;304:967–975. PubMed PMC

Bijron JG, Seldenrijk CA, Zweemer RP, et al. Fallopian tube intraluminal tumor spread from noninvasive precursor lesions: a novel metastatic route in early pelvic carcinogenesis. Am J Surg Pathol. 2013;37:1123–1130. PubMed

Maritschnegg E, Wang Y, Pecha N, et al. Lavage of the uterine cavity for molecular detection of müllerian duct carcinomas: a proof-of-concept study. J Clin Oncol. 2015;33:4293–4300. PubMed PMC

Kinde I, Bettegowda C, Wang Y, et al. Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers. Sci Transl Med. 2013;5: 167ra4. PubMed PMC

Erickson BK, Kinde I, Dobbin ZC, et al. Detection of somatic TP53 mutations in tampons of patients with high-grade serous ovarian cancer. Obstet Gynecol. 2014;124:881–885. PubMed PMC

Rogstad KE, White DJ, Ahmed-Jushuf IH. Efficacy of lignocaine analgesia during treatment to the cervix. Lancet. 1992;340:942. PubMed

Jacobs I, Stabile I, Bridges J, et al. Multimodal approach to screening for ovarian cancer. Lancet. 1988;1:268–271. PubMed

Schwartz MD, Kaufman E, Peshkin BN. Bilateral prophylactic oophorectomy and ovarian cancer screening following BRCA1/BRCA2 mutation testing. J Clin Oncol. 2003;21:4034–4041. PubMed

Lerman C, Hughes C, Croyle RT. Prophylactic surgery decisions and surveillance practices one year following BRCA1/2 testing. Prev Med. 2000;31:75–80. PubMed

Meijers-Heijboer H, Brekelmans CT, Menke-Pluymers M. Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation. J Clin Oncol. 2003;21:1675–1681. PubMed

Meijers-Heijboer EJ, Verhoog LC, Brekelmans CT. Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation. Lancet. 2000;355:2015–2020. PubMed

Lodder LN, Frets PG, Trijsburg RW. One year follow-up of women opting for presymptomatic testing for BRCA1 and BRCA2: emotional impact of the test outcome and decisions on risk management (surveillance or prophylactic surgery). Breast Cancer Res Treat. 2002;73:97–112. PubMed

Scheuer L, Kauff N, Robson M. Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol. 2002;20:1260–1268. PubMed

Botkin JR, Smith KR, Croyle RT. Genetic testing for a BRCA1 mutation: prophylactic surgery and screening behavior in women 2 years post testing. Am J Med Genet A. 2003;118A:201–209. PubMed

Claes E, Evers-Kiebooms G, Decruyenaere M. Surveillance behavior and prophylactic surgery after predictive testing for hereditary breast/ovarian cancer. Behav Med. 2005;31:93–105. PubMed

Madalinska JB, van Beurden M, Bleiker EM, et al. Predictors of prophylactic bilateral salpingo-oophorectomy compared with gynecologic screening use in BRCA1/2 mutation carriers. J Clin Oncol. 2007;25:301–307. PubMed

Skytte AB, Gerdes AM, Andersen MK, et al. Risk-reducing mastectomy and salpingo-oophorectomy in unaffected BRCA mutation carriers: uptake and timing. Clin Genet. 2010;77:342–349. PubMed

McNaughton C, Zhou C, Robert L, et al. A randomized, crossover comparison of injected buffered lidocaine, lidocaine cream, and no analgesia for peripheral intravenous cannula insertion. Ann Emerg Med. 2009;54:214–220. PubMed

Akers AY, Steinway C, Sonalkar S, et al. Reducing pain during intrauterine device insertion: a randomized controlled trial in adolescents and young women. Obstet Gynecol. 2017;130:795–802. PubMed

Krimmel JD, Schmitt MW, Harrell MI, et al. Ultra-deep sequencing detects ovarian cancer cells in peritoneal fluid and reveals somatic TP53 mutations in noncancerous tissues. Proc Natl Acad Sci U S A. 2016;113:6005–6010. PubMed PMC